High prevalence of the risk factors for QT interval prolongation and associated drug-drug interactions in coronary care units

Postgraduate Medicine
Qasim KhanIqbal Haider

Abstract

Patients admitted in coronary care units are susceptible to QT interval prolongation due to numerous risk factors. The purpose of this study was to identify the prevalence of risk factors for QT interval prolongation; QT prolonging medications; drug-drug interactions; their predictors; and torsades de pointes risks of drugs. After obtaining approval, this cross-sectional study was carried out during one-year period in coronary care units of two major tertiary care hospitals of Khyber Pakhtunkhwa, Pakistan. The Arizona Center for Education and Research on Therapeutics QT drugs lists and Micromedex DrugReax® were used to identify the QT prolonging medications and QT prolonging drug-drug interactions. Total 649 patients were included in this study. The most frequent QT prolonging risk factors included use of ≥ 1 QT prolonging drugs (74.9%) and myocardial infarction (61.3%). Total 181 patients were presented with 361 QT prolonging drug-drug interactions. There was significant association of the occurrence of QT prolonging drug-drug interactions with female gender (p = 0.01), 9-10 prescribed medications (p = 0.001), and > 10 prescribed medications (p < 0.001). The majority of patients presented with multiple risk factors for QT prol...Continue Reading

References

Feb 15, 2003·The American Journal of Medicine·Lesley H CurtisKevin A Schulman
Nov 5, 2003·Heart·Yee Guan Yap, A John Camm
Mar 5, 2004·The New England Journal of Medicine·Dan M Roden
Sep 24, 2005·Pharmacoepidemiology and Drug Safety·Nancy M Allen LaPointeRichard Platt
May 16, 2006·Pharmacoepidemiology and Drug Safety·Pascale Olivier, Jean-Louis Montastruc
Oct 13, 2006·QJM : Monthly Journal of the Association of Physicians·D A Gorard
Dec 5, 2006·Current Opinion in Cardiology·Prince J Kannankeril, Dan M Roden
Feb 27, 2010·Journal of the American College of Cardiology·Barbara J DrewUNKNOWN American College of Cardiology Foundation
Apr 10, 2010·Expert Opinion on Drug Safety·Pamela L SmithburgerSandra L Kane-Gill
Sep 4, 2010·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Pamela L SmithburgerAmy L Seybert
Jan 15, 2013·Journal of Critical Care·Michael J ArmahizerSandra L Kane-Gill
May 30, 2013·Circulation. Cardiovascular Quality and Outcomes·James E TisdaleRichard J Kovacs
Apr 12, 2016·British Journal of Clinical Pharmacology·Paula Andrea Moreno-GutiérrezJorge Enrique Machado-Alba
Feb 24, 2018·Current Clinical Pharmacology·Cecilia Villa EtchegoyenGuillermo Di Girolamo
Jun 14, 2018·PloS One·Flávia Medeiros FernandesAntonio Gouveia Oliveira

❮ Previous
Next ❯

Citations

Apr 30, 2020·Circulation. Arrhythmia and Electrophysiology·Moussa SalehLaurence M Epstein
Nov 10, 2020·International Journal of Antimicrobial Agents·Teodoro J OscanoaRoman Romero-Ortuno
Feb 10, 2021·International Journal of Clinical Practice·Nada A SaadRaghda R S Hussein

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.